Search - tctmd.com

Displaying 101 - 120 of 237

Sort: Relevancy | Date

Enlarged Left Atria Can ID Patients With ESUS Who May Benefit From a DOAC

News Daily News

Enlarged Left Atria Can ID Patients With ESUS Who May Benefit From a DOAC

April 08, 2019

Edoxaban Joins Other NOACs as Option During Catheter Ablation for A-fib

News Conference News EHRA 2019

Edoxaban Joins Other NOACs as Option During Catheter Ablation for A-fib

March 21, 2019

DOACs in Patients With Mitral Stenosis and A-fib: Analysis Suggests a Benefit

News Daily News

DOACs in Patients With Mitral Stenosis and A-fib: Analysis Suggests a Benefit

March 12, 2019

Rivaroxaban in Addition to DAPT Lowers Death, MI, Stroke in ACS, Heart Failure Patients: Meta-analysis

News Conference News CRT 2019

Rivaroxaban in Addition to DAPT Lowers Death, MI, Stroke in ACS, Heart Failure Patients: Meta-analysis

Yael L. Maxwell

March 03, 2019

Final ANNEXA-4 Results Published, Confirm Rapid Andexanet Alfa Effects

News Conference News ISC 2019

Final ANNEXA-4 Results Published, Confirm Rapid Andexanet Alfa Effects

February 13, 2019

Go With NOACs Over Warfarin in Most Cases: Updated A-fib Guidelines

News Daily News

Go With NOACs Over Warfarin in Most Cases: Updated A-fib Guidelines

January 29, 2019

Continuing Anticoagulation During TAVR in A-fib Patients May Be Safe, Study Suggests

News Daily News

Continuing Anticoagulation During TAVR in A-fib Patients May Be Safe, Study Suggests

January 09, 2019

Top News in Endovascular Therapy: 2018

News Features

Top News in Endovascular Therapy: 2018

December 28, 2018

Complications Following TAVR Are Going Down, US Data Show

News Conference News AHA 2018

Complications Following TAVR Are Going Down, US Data Show

Yael L. Maxwell

November 20, 2018

Consulting the COMPASS for Rivaroxaban’s Role in Peripheral Vascular Disease

News Conference News VIVA 2018

Consulting the COMPASS for Rivaroxaban’s Role in Peripheral Vascular Disease

November 15, 2018

Rivaroxaban Lowers Thromboembolic Risk in HF Patients: COMMANDER HF

News Conference News AHA 2018

Rivaroxaban Lowers Thromboembolic Risk in HF Patients: COMMANDER HF

November 11, 2018

Dabigatran Trials Come Up Short for Stroke of Unknown Cause and Cerebral Venous Thrombosis

News Daily News

Dabigatran Trials Come Up Short for Stroke of Unknown Cause and Cerebral Venous Thrombosis

October 26, 2018

FDA Approves Rivaroxaban for CV Event Reduction in CAD and PAD Patients

News Daily News

FDA Approves Rivaroxaban for CV Event Reduction in CAD and PAD Patients

October 12, 2018

GALILEO Trial of Rivaroxaban After TAVR Stopped Early for Harm

News Daily News

GALILEO Trial of Rivaroxaban After TAVR Stopped Early for Harm

October 09, 2018

DOACs Safe, Effective in A-fib Patients With Preexisting LAA Thrombus

News Daily News

DOACs Safe, Effective in A-fib Patients With Preexisting LAA Thrombus

October 04, 2018

Stay Away From Warfarin-Based Triple Therapy in Patients With A-fib and CAD, Study Affirms

News Daily News

Stay Away From Warfarin-Based Triple Therapy in Patients With A-fib and CAD, Study Affirms

October 03, 2018

COMMANDER HF: Low-Dose Rivaroxaban Flops in Heart Failure

News Conference News ESC 2018

COMMANDER HF: Low-Dose Rivaroxaban Flops in Heart Failure

August 27, 2018

MARINER Fails to Meet Primary Endpoint Testing Rivaroxaban for Extended VTE Thromboprophylaxis

News Conference News ESC 2018

MARINER Fails to Meet Primary Endpoint Testing Rivaroxaban for Extended VTE Thromboprophylaxis

August 26, 2018

ESC 2018: Trimming DAPT, New NOAC Niches, Aspirin Scrutiny for Primary Prevention, and More

News Conference News ESC 2018

ESC 2018: Trimming DAPT, New NOAC Niches, Aspirin Scrutiny for Primary Prevention, and More

August 20, 2018

Edoxaban Looks Good for Asians With A-fib in Real-world Analysis

News Daily News

Edoxaban Looks Good for Asians With A-fib in Real-world Analysis

August 14, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.